Condition

Renal Cell Carcinoma clinical trials and research

• 78Clinical trials
• 63NIH research projects
• 2New in 30 days
• 29Countries

Newest Renal Cell Carcinoma clinical trials

All recruiting trials (78)

• Plasma DNA Methylation to Classify Kidney Masses Before Surgery

  This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07874542

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Intensified monitoring to personalize cabozantinib dosing in advanced kidney cancer

  We will test whether closer pharmacology-based monitoring helps people with advanced kidney cancer tolerate cabozantinib better while keeping its effect against the cancer.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordenone · NCT07805122

• Who’s at high risk after RCC surgery? Real-world clues from French registry

  This study looks at real-world data from French RCC patients who had local or high-risk locally advanced disease to see how they do after surgery and how doctors decide on adjuvant treatment.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07753343

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

• Cold ischemia during robot-assisted partial nephrectomy

  This trial will test whether using ice around the kidney during robot-assisted partial nephrectomy helps the operated kidney recover function faster in adults with kidney cancer.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07326280

• PET imaging that targets PSMA, CAIX, and CD70 to detect and stage renal cell carcinoma.

  This project will test whether PET scans that target PSMA, CAIX, and CD70 can accurately detect and map renal cell carcinoma in adults with suspected or confirmed disease and in healthy volunteers.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07301827

• NEO-811 for advanced or metastatic clear cell kidney cancer

  This study will try the experimental oral drug NEO-811 in people with locally advanced or metastatic clear cell kidney cancer who have progressed on or refused standard treatments.

  Recruiting at 16 sites Phase 1 Neomorph, Inc · Duarte, California and 15 other locations · NCT07300241

• GCAR1 CAR-T therapy for GPNMB-expressing solid tumours

  This study tests different doses of GCAR1 CAR-T cells in people with specific cancers that make high levels of the GPNMB protein to see if the treatment is safe and how it affects the cancer.

  Recruiting at 3 sites Phase 1 Canadian Cancer Trials Group · Calgary, Alberta and 3 other locations · NCT07297667

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Belzutifan plus zanzalintinib versus cabozantinib for recurrent advanced kidney cancer after adjuvant PD-1/L1 therapy

  This study will test whether taking belzutifan together with zanzalintinib helps people with recurrent advanced kidney cancer live longer and keep the cancer from getting worse compared with cabozantinib after prior adjuvant PD-1/L1 therapy.

  Recruiting at 127 sites Phase 3 Merck Sharp & Dohme LLC · Anchorage, Alaska and 126 other locations · NCT07227402

• Subcutaneous versus intravenous immune therapy: which do patients prefer?

  This project will test whether patients with advanced cancers prefer subcutaneous (under‑the‑skin) versus intravenous nivolumab or, if available, pembrolizumab.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07223424

• Retifanlimab plus ruxolitinib for advanced kidney and lung cancers

  This trial will test whether taking ruxolitinib twice daily together with retifanlimab infusions every 4 weeks is safe and can help people with metastatic renal cell carcinoma or non-small cell lung cancer who progressed on prior PD-1/PD-L1 therapy.

  Recruiting Phase 1/2 University of California, San Diego · La Jolla, California · NCT07219576

• First human testing of BMS-986506 in advanced clear cell kidney cancer

  This will test whether the experimental drug BMS-986506 is safe and tolerable when taken alone by people with advanced or metastatic clear cell kidney cancer who have already received prior treatments.

  Recruiting at 9 sites Phase 1 Bristol-Myers Squibb · Boston, Massachusetts and 10 other locations · NCT07195682

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Combining sasanlimab, palbociclib, and axitinib for metastatic kidney cancer

  This test tries a combination of sasanlimab, palbociclib, and axitinib in people with advanced or metastatic clear cell or translocation renal cell carcinoma to see if it works and is safe.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07123090

• Testing AZD6750 safety in adults with selected advanced or metastatic solid tumors

  This trial tests whether AZD6750, a CD8-guided IL-2 medicine given alone or with other cancer drugs, is safe and how it behaves in adults with certain advanced or metastatic solid tumors.

  Recruiting at 13 sites Phase 1/2 AstraZeneca · Grand Rapids, Michigan and 12 other locations · NCT07115043

• Combination belzutifan plus zanzalintinib for recurrent clear cell renal cell carcinoma after anti‑PD‑(L)1 adjuvant therapy

  This study tests whether combining belzutifan and zanzalintinib is safe and active for people whose clear cell renal cell carcinoma came back during or within 24 months after anti‑PD‑(L)1 adjuvant therapy.

  Recruiting at 33 sites Phase 1/2 Merck Sharp & Dohme LLC · San Francisco, California and 32 other locations · NCT07049926

• Tracking TTV viral load during first-line immunotherapy for renal cell carcinoma

  This project will test whether changes in torquetenovirus (TTV) levels in blood and stool can help predict how people with metastatic clear cell renal cell carcinoma respond to first-line immunotherapy.

  Recruiting Regina Elena Cancer Institute · Rome, Rome · NCT07018037

• High-dose radiotherapy for renal cell carcinoma treatment

  This study is testing whether a higher dose of radiation therapy can be a better option for people with kidney cancer compared to the standard treatment.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT06995664

• DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers

  This trial will test whether the oral drug DCC-2812 is safe and shows early signs of benefit for people with advanced kidney (renal cell), bladder (urothelial), or castration-resistant prostate cancer.

  Recruiting at 8 sites Phase 1 Deciphera Pharmaceuticals, LLC · Boston, Massachusetts and 7 other locations · NCT06966024

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Total Consolidative Metastasis and Primary-directed Therapy for Renal Cell Carcinoma

  This study tests whether giving a one-time consolidative treatment to all detectable disease, then stopping systemic therapy, can keep people with metastatic clear cell RCC progression-free for 12 months after at least 6 months of immune therapy.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT06770855

• Using cemiplimab and fianlimab before kidney cancer surgery

  This study is testing whether giving two immunotherapy drugs before kidney cancer surgery can safely shrink tumors in patients with high-risk non-metastatic clear cell renal cell carcinoma.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06699602

• Evaluating a new CAR T-cell therapy for solid tumors expressing EGFR

  This study is testing a new CAR T-cell therapy to see if it can safely help adults with certain solid tumors, like colorectal and lung cancer, that have specific markers.

  Recruiting at 10 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 9 other locations · NCT06682793

• Investigating QXL138AM for patients with advanced solid tumors and multiple myeloma

  This study is testing a new drug called QXL138AM to see if it can safely help people with advanced solid tumors and multiple myeloma.

  Recruiting at 11 sites Phase 1 Nammi Therapeutics Inc · Los Angeles, California and 10 other locations · NCT06582017

• Using a digital tool to improve kidney surgery planning

  This study is testing a new digital tool to see if it helps doctors plan kidney surgery better for patients with localized kidney cancer compared to just using regular CT scans.

  Recruiting at 5 sites University Hospital, Ghent · Aalst and 4 other locations · NCT06536439

• Treatment of advanced solid tumors with VET3-TGI immunotherapy

  This study is testing a new cancer treatment called VET3-TGI to see if it can safely target and kill cancer cells in patients with advanced solid tumors, either by injecting it directly into the tumors or giving it through an IV.

  Recruiting at 7 sites Phase 1 KaliVir Immunotherapeutics · Los Angeles, California and 6 other locations · NCT06444815

• Proton therapy for kidney cancer treatment

  This study is testing if proton therapy can help people with kidney cancer who can't have surgery by improving their treatment outcomes while protecting their healthy kidney tissue.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Washington D.C., District of Columbia · NCT06376669

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Monitoring small kidney tumors without immediate surgery

  This study is testing whether people with small kidney tumors can safely skip surgery and be monitored instead, to see how well they do over time.

  Recruiting Azienda Ospedaliero Universitaria Maggiore della Carita · Novara · NCT06336187

• Comparing home and clinic administration of nivolumab for cancer treatment

  This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT06265285

• Intratumoral injection of GM103 for advanced solid tumors

  This study is testing a new virus treatment called GM103, alone and with another drug, to see if it can help people with advanced solid tumors that are hard to treat.

  Recruiting Phase 1/2 GeneMedicine Co., Ltd. · Goyang-si, Gyeonggi-do and 3 other locations · NCT06265025

• Multimodal radiotherapy for advanced renal cell carcinoma after immunotherapy

  This study is testing whether combining different types of radiation therapy with ongoing treatment can help people with advanced kidney cancer who haven't responded well to previous immunotherapy.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT06255223

• Testing HC-7366 with Belzutifan for kidney cancer treatment

  This study is testing a new treatment combining HC-7366 with belzutifan to see if it helps people with advanced kidney cancer feel better and live longer.

  Recruiting at 19 sites Phase 1 HiberCell, Inc. · Tucson, Arizona and 20 other locations · NCT06234605

• Precision treatment for kidney cancer based on proteomic analysis

  This study is testing personalized treatment options for kidney cancer patients by grouping them based on their tumor's characteristics to see which combination of drugs works best for them.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06211790

• Combining local therapies with systemic treatment for certain cancers

  This study is testing if adding local treatments like targeted radiation or ablation can help people with certain types of cancer, such as prostate or kidney cancer, stay on their main treatment longer without needing changes.

  Recruiting University of California, Davis · Sacramento, California · NCT06101290

• Using PET/MR to identify types of kidney tumors

  This study is testing if a new type of imaging can help doctors tell the difference between aggressive and harmless kidney tumors in people with certain kidney masses.

  Recruiting at 2 sites University of Texas Southwestern Medical Center · Dallas, Texas and 1 other locations · NCT06076538

• Combining tivozanib and nivolumab for advanced non-clear cell kidney cancer

  This study tests if combining two medications, tivozanib and nivolumab, can help people with advanced non-clear cell kidney cancer manage their disease better.

  Recruiting at 6 sites Phase 2 M.D. Anderson Cancer Center · Irvine, California and 5 other locations · NCT06053658

• Testing NEO212 for treating certain brain tumors and metastases

  This study is testing a new treatment called NEO212 for people with certain types of brain tumors to see if it is safe and effective when combined with standard treatments.

  Recruiting at 8 sites Phase 1/2 Neonc Technologies, Inc. · Beverly Hills, California and 7 other locations · NCT06047379

• Combining Pembrolizumab and Axitinib for Kidney Cancer with Tumor Thrombus

  This study is testing whether combining two medications, Pembrolizumab and Axitinib, can help shrink kidney cancer tumors that have spread to a major vein before surgery.

  Recruiting at 3 sites Phase 2 University of Colorado, Denver · Aurora, Colorado and 2 other locations · NCT05969496

• Higher dose of cabozantinib for advanced kidney cancer

  This study is testing whether a higher dose of cabozantinib can help people with advanced kidney cancer who didn’t respond to previous treatment with the same drug.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT05931393

• Monitoring kidney cancer using blood tests for DNA changes

  This study is testing if blood tests that look for DNA changes can help track kidney cancer in patients before and after surgery.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT05917106

• Comparing two radiation therapy techniques for advanced solid tumors

  This study is testing whether a new type of radiation therapy works better than the standard method for treating advanced solid tumors that have spread, to see if it can improve outcomes for patients needing palliative care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05837767

• Using PET scans to guide targeted radiation therapy for certain cancers

  This study is testing if using PET scans to guide targeted radiation therapy can help people with certain cancers, like lung cancer and melanoma, get better results than standard treatment.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT05830058

• Comparing pain relief methods after kidney surgery

  This study is testing two different pain relief methods after kidney surgery to see which one helps patients feel better and use less morphine.

  Recruiting Kocaeli University · İzmit and 1 other locations · NCT05810571

• Alectinib treatment for ALK-positive cancers in adults and children

  This study is testing if alectinib, a drug for lung cancer, can help treat different types of ALK-positive cancers in both adults and children.

  Recruiting at 24 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT05770037

• Combining Axitinib and PD-1 to Improve Outcomes in Kidney Cancer

  This study is testing if a combination of axitinib and PD-1 therapy can help kidney cancer patients who are at high risk of their cancer coming back after surgery.

  Recruiting at 8 sites Phase 3 Sun Yat-sen University · Beijing and 7 other locations · NCT05738694

• Using pembrolizumab and lenvatinib to treat kidney cancer before surgery

  This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, can help treat kidney cancer before surgery to see how well they work together.

  Recruiting Early Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT05733715

• Testing a microdevice for drug delivery in kidney cancer

  This study is testing a tiny device that delivers small amounts of cancer drugs directly to kidney tumors to see if it helps people with advanced kidney cancer.

  Recruiting Phase 1 Brigham and Women's Hospital · Boston, Massachusetts · NCT05700461

• Using contrast-enhanced ultrasound to diagnose recurrent kidney cancer after treatment

  This study is testing if a special type of ultrasound can better detect kidney cancer that comes back after treatment compared to regular imaging methods like CT and MRI.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT05641935

• Personalizing cancer therapy by measuring immune suppression

  This study is testing whether measuring certain immune cells in cancer patients can help tailor their treatments and understand how feelings of isolation might affect their immune system.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT05621837

• Evaluating decision aids for patients with renal cell carcinoma

  This study is testing two decision aids to see if they can help patients with renal cell carcinoma make better treatment choices and feel more confident about their decisions.

  Recruiting St. Antonius Hospital · Nieuwegein, Utrecht · NCT05548621

• CD70-targeted CAR-T therapy for advanced solid tumors

  This study is testing a new type of CAR-T therapy that targets CD70 to see if it can safely help people with advanced solid tumors.

  Recruiting Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT05518253

• Nationwide cohort for renal cell carcinoma data collection

  This study is collecting real-life health information from people with kidney cancer in the Netherlands to help improve treatments and understand their experiences better.

  Recruiting at 27 sites PROspective Renal Cancer Cohort Foundation · Amsterdam, North Holland and 26 other locations · NCT05326620

• Combining lenvatinib and pembrolizumab before surgery for advanced kidney cancer with IVC tumor thrombus

  This study is testing if combining two medications, lenvatinib and pembrolizumab, before surgery can help shrink advanced kidney cancer that has spread to a major vein and improve surgery results.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT05319015

• Observing cancer recurrence using a blood test

  This study is testing a new blood test to see if it can help find out if cancer comes back in people who have been treated for early-stage solid tumors.

  Recruiting at 49 sites Guardant Health, Inc. · Birmingham, Alabama and 56 other locations · NCT05059444

• Combining nivolumab, ipilimumab, and cabozantinib for untreated kidney cancer that has spread to the brain

  This trial tests whether adding the oral drug cabozantinib to two immunotherapy medicines (nivolumab and ipilimumab) helps people with untreated renal cell carcinoma brain metastases live longer or have their brain tumors shrink.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05048212

• Exploring the gut microbiome's role in cancer treatment response

  This study is testing how the bacteria in the gut might affect how well cancer patients respond to a specific type of treatment called immune checkpoint inhibitors.

  Recruiting VastBiome · Elizabethtown, Kentucky · NCT05037825

• Combining Envafolimab and Lenvatinib for treating advanced solid tumors

  This study is testing if combining two drugs, Envafolimab and Lenvatinib, can help people with advanced solid tumors feel better when other treatments haven't worked.

  Recruiting at 16 sites Phase 1/2 3D Medicines · Bengbu, Anhui and 22 other locations · NCT05024214

• Quality of life and outcomes after SBRT for primary kidney cancer

  This trial will test whether stereotactic body radiotherapy (SBRT) helps people with primary kidney cancer who cannot or will not have surgery and how it affects their quality of life.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT05023265

• Imaging study using [18F]PT2385 for renal cell carcinoma

  This study is testing a new imaging method using [18F]PT2385 to see if it can help understand tumor characteristics in people with renal cell carcinoma.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT04989959

• Combining three medications for advanced kidney cancer treatment

  This study is testing a combination of three medications to see if they can help people with advanced kidney cancer feel better and live longer.

  Recruiting at 6 sites Phase 2 National Cancer Institute (NCI) · La Jolla, California and 12 other locations · NCT04981509

• Using targeted radiation therapy for patients with limited progression of kidney cancer on immune therapy

  This study is testing if a special type of radiation therapy can help people with kidney cancer who are seeing limited growth while on immune therapy feel better and live longer.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT04974671

• Combining immune checkpoint inhibitors with radiotherapy for cancer treatment

  This study is testing if combining immune checkpoint inhibitors with radiotherapy can improve treatment for patients with certain types of cancer, like head and neck and lung cancer.

  Recruiting University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria · NCT04892849

• Understanding BAP1 Hereditary Cancer Risks

  This study is trying to find out how common certain cancers are in people with BAP1 gene mutations to help improve screening and treatment for them and their families.

  Recruiting Ohio State University · Columbus, Ohio · NCT04792463

• Evaluating the safety and effectiveness of ST-067 in treating various solid tumors

  This study is testing a new treatment called ST-067 to see if it can help people with tough-to-treat solid tumors feel better and improve their health.

  Recruiting at 6 sites Phase 1/2 Simcha IL-18, Inc. · Scottsdale, Arizona and 5 other locations · NCT04787042

• Understanding how kidney tumors use nutrients for growth

  This study tests how kidney tumors use certain nutrients to grow by giving participants a special nutrient infusion during surgery and checking their blood and tissue samples.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT04623502

• Collection of tumor samples from cancer patients for diagnostic test development

  This study is collecting tumor samples from cancer patients who are getting certain treatments to help create better tests for managing cancer in the future.

  Recruiting Cofactor Genomics, Inc. · San Francisco, California · NCT04510129

• Testing a new treatment for advanced solid tumors with pembrolizumab

  This study is testing a new treatment using INBRX-106 alone and with pembrolizumab to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 17 sites Phase 1/2 Inhibrx Biosciences, Inc · Duarte, California and 59 other locations · NCT04198766

• Microwave ablation for treating small kidney and liver tumors

  This study is testing whether microwave ablation can safely and effectively treat small kidney and liver tumors in patients while they continue their regular care.

  Recruiting IRCCS San Raffaele · Milan · NCT03981497

• Olaparib treatment for patients with metastatic kidney cancer and specific gene mutations

  This study is testing if the oral medication olaparib can help people with advanced kidney cancer who have certain gene mutations and have already tried other treatments.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT03786796

• Combining pazopanib with abexinostat for advanced kidney cancer

  This study is testing whether combining two drugs, pazopanib and abexinostat, can help people with advanced kidney cancer live longer without their disease getting worse compared to just taking pazopanib alone.

  Recruiting Phase 3 Xynomic Pharmaceuticals, Inc. · Phoenix, Arizona and 37 other locations · NCT03592472

• National registry for patients with advanced kidney and bladder cancer

  This study is setting up a national registry to track the experiences and treatments of patients with advanced kidney and bladder cancer over a few years to help improve care and research in the future.

  Recruiting iOMEDICO AG · Multiple Locations · NCT03374267

• Testing new treatments for kidney cancer after surgery

  This study is testing if a new kidney cancer treatment, either by itself or in combination, can help patients stay cancer-free longer after surgery compared to just monitoring their health.

  Recruiting at 35 sites Phase 3 University College, London · Aberdeen and 34 other locations · NCT03288532

• Infusing iNKT and PD-1+ CD8+ T cells for advanced solid tumors

  This study will try giving people with advanced lung, pancreatic, liver, stomach, or colon cancers infusions of iNKT cells and PD-1+ CD8+ T cells to see if tumors shrink and survival improves.

  Recruiting Phase 1/2 Shanghai Public Health Clinical Center · Shanghai, Shanghai Municipality · NCT03093688

• Investigating inherited kidney and urologic cancers

  This study is trying to learn more about inherited kidney and urologic cancers by looking at families with these conditions to see how they develop and what genetic factors are involved.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00001238

NIH-funded research (newest 40 of 63)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding how kidney cancer spreads to bone and how to fight it

  A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11446651

• Improve precision medicine for kidney cancer in people of African descent

  A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11433340

• Engineering immunogenic cell death to boost melanoma and kidney cancer therapy

  This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11415156

• Prognostic test to predict metastasis in clear cell kidney cancer

  A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.

  NIH research Lagrange Scientific, LLC · Pewee Valley, United States · NIH-11412572

• Defining metabolic targets in kidney cancer for new treatments

  A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11400752

• Targeting HIF2 in kidney cancer: a new approach for clear cell RCC

  A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11400746

• How mitochondrial activity and cancer spread are affected by tRNA changes in kidney cancer

  This project looks at how specific tRNA modifications influence mitochondrial function and the spread of kidney cancer.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11382273

• Exploring KEAP1 Mutations and Hereditary Kidney Cancer Susceptibility

  This grant supports a clinician-scientist in studying how KEAP1 gene changes may increase the risk of hereditary kidney cancer and what this means for screening and targeted treatment.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11381070

• Targeting NRF2 signaling in a rare kidney cancer subtype (tRCC)

  Aimed at a specific, aggressive kidney cancer called translocation RCC, this project explores how NRF2 pathway activation happens and whether blocking it could help treat patients.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11371133

• Biomarkers to predict relapse risk in localized clear cell kidney cancer

  A clinician-scientist is studying blood and tissue biomarkers to identify which kidney cancer patients are at higher risk of returning after tumor removal.

  NIH research University of California at Davis · Davis, United States · NIH-11369856

• Understanding how fusion proteins drive a pediatric kidney cancer

  A Johns Hopkins-led study will explore how specific fusion proteins form inside cancer cells to reveal new targets for treating pediatric kidney cancer called tRCC.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11366037

• Targeting CDH17 with T cell therapy for translocation renal cell carcinoma

  Aims to see if a cancer-targeting immune treatment can help patients with a hard-to-treat kidney cancer called translocation RCC.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11363781

• Targeted therapy approach for translocation renal cell carcinoma

  A study at SUNY Buffalo aims to find small molecules that block a key protein interaction driving a rare kidney cancer to help patients who have a specific genetic form of the disease.

  NIH research State University of New York at Buffalo · Amherst, United States · NIH-11351015

• Tumor and immune factors that drive anti-tumor immune responses in kidney cancer

  This grant looks at why some people with advanced kidney cancer respond to immune therapies and others don’t, with a focus on how immune cells inside tumors interact with cancer cells.

  NIH research Yale University · New Haven, United States · NIH-11350959

• Biomarkers to predict and understand response to anti-PD-1 therapy in metastatic kidney cancer

  This grant tests tissue clues like immune cells and tumor targets to figure out why some patients with metastatic kidney cancer respond to anti-PD-1 therapy while others do not.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11346038

• Targeted VEGF-blocking CAR-T cells to boost kidney cancer therapy

  A patient-focused look at using engineered CAR-T cells that block VEGF right at the tumor to improve treatment for kidney cancer.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11332290

• Targeting lactic acid sensing to treat clear cell renal cell carcinoma

  A new NIH grant explores how lactic acid in the tumor environment helps this kidney cancer grow, and tests whether blocking a lactate-sensing receptor can slow or stop the disease.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11306321

• How tumor metabolism blocks T cells in clear cell kidney cancer

  Looking at whether changing how tumors use nutrients helps immune T cells attack clear cell kidney cancer.

  NIH research University of Chicago · Chicago, United States · NIH-11305244

• New combination therapies for non-clear cell kidney cancer

  Combining JAK and AKT blockers with drugs that stop cancer cells from switching to burning fats to try to help people with non-clear cell kidney cancer.

  NIH research Oregon Health & Science University · Portland, United States · NIH-11294318

• Could kidney-made glucose help kidney cancer grow?

  This project tests whether extra glucose produced by the kidney helps renal cell carcinoma grow, aiming to help people with kidney cancer.

  NIH research Yale University · New Haven, United States · NIH-11285165

• Gut bacteria and immunotherapy outcomes in advanced kidney cancer

  This project compares people’s gut bacteria to their responses and side effects from immunotherapy for advanced kidney cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11284115

• Optimizing anti-PD-1 therapy for localized kidney cancer

  This grant aims to improve how anti-PD-1 immunotherapy is used before and after surgery to help people with localized kidney cancer who are at high risk of relapse.

  NIH research Brigham and Women's Hospital · Boston, United States · NIH-11277056

• Blocking CDK4/6 to treat MiT/TFE-translocation kidney cancer

  This project tests whether drugs that block CDK4/6, alone or with PI3K/mTOR blockers, can slow an aggressive kidney cancer caused by MiT/TFE gene fusions.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11267961

• How the FTO protein changes metabolism in clear cell kidney cancer

  Researchers are looking to see if blocking the FTO protein can slow growth of VHL-deficient clear cell kidney cancer cells.

  NIH research Stanford University · Stanford, United States · NIH-11262192

• KIM-1 blood test to find and follow kidney cancer

  This project tests whether a blood test for the protein KIM-1 can help find and monitor kidney cancer in people with small kidney tumors, after surgery, and with metastatic disease.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11247583

• Blocking ANGPTL4 to treat clear cell kidney cancer

  Researchers aim to block a protein called ANGPTL4 to slow tumor growth and normalize blood vessels in clear cell kidney cancer so immunotherapy may work better for patients.

  NIH research University of Florida · Gainesville, United States · NIH-11247570

• Making melanoma and kidney cancer cell death trigger stronger immune responses

  This project aims to reprogram how melanoma and renal cell carcinoma cells die so their death sparks a bigger immune attack and helps more patients benefit from immunotherapy.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11176082

• MRI fingerprinting to better identify types of kidney tumors

  This project tests a new MRI technique to noninvasively tell apart benign or low-grade kidney masses from aggressive kidney cancers in people with renal tumors.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-11171640

• Blocking HIF2 in clear cell kidney cancer

  This project gives drugs that block a protein called HIF2 to people with clear cell kidney cancer to try to stop tumor growth and delay or overcome resistance.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11145066

• Understanding and treating a specific kidney cancer called tRCC

  This project looks for new ways to treat a rare and aggressive kidney cancer called translocation renal cell carcinoma (tRCC) by focusing on a specific cell pathway.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11144442

• Test to predict whether clear-cell kidney cancer will spread

  A 12-marker tissue test is being developed to predict which people with clear-cell renal cell carcinoma are likely to develop metastatic disease.

  NIH research Lagrange Scientific, LLC · Pewee Valley, United States · NIH-11141802

• New treatments for a rare kidney cancer

  This research looks for new ways to stop the growth of a rare and aggressive type of kidney cancer called translocation renal cell carcinoma.

  NIH research State University of New York at Buffalo · Amherst, United States · NIH-11132968

• Finding clues in tissue to improve kidney cancer treatment

  This project looks for clues in tumor tissue to understand why some patients with advanced kidney cancer respond to immunotherapy and others do not.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11094731

• Understanding how cancer cells affect T cell activation in kidney cancer

  This study is looking at how clear cell kidney cancer affects the immune system's T cells, which help fight cancer, by changing the way cancer cells use sugar and other nutrients, and it hopes to find new ways to boost T cell activity for better treatment options.

  NIH research Vanderbilt University Medical Center · Nashville, United States · NIH-11061783

• Exploring how certain kidney cancer cells change and spread

  This study is looking at a tough type of kidney cancer called sarcomatoid renal cell carcinoma to find out how certain changes in the cancer cells might help it grow and spread, with the goal of discovering new treatment options that could work better for patients like you.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11061417

• Investigating how YAP/TAZ proteins affect kidney cancer

  This study is looking at how certain proteins called YAP and TAZ affect kidney cancer and hopes to find out if blocking them can change how cancer cells behave, which could help develop new treatments for people with kidney cancer.

  NIH research Georgetown University · Washington, United States · NIH-11061291

• The role of gut bacteria in cancer treatment outcomes for kidney cancer patients

  This study is looking at how the bacteria in your gut might influence how well immunotherapy works for people with advanced kidney cancer, aiming to find out which gut bacteria can help predict treatment success and side effects, so doctors can better personalize care for each patient.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11060888

• Understanding how certain immune cells affect T cell function in kidney cancer treatment

  This study is looking at how certain immune cells called tumor-associated macrophages affect kidney cancer and how they might change the way your body responds to treatment, with the goal of finding better ways to help patients like you.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11051217

• Creating new combination therapies for a type of kidney cancer

  This study is exploring new treatment options for people with Non-Clear Cell Renal Cell Carcinoma, a tough type of kidney cancer, by testing a mix of two drugs that could help stop the cancer from growing and surviving.

  NIH research Oregon Health & Science University · Portland, United States · NIH-11047661

• Investigating the role of a protein in aggressive kidney cancer and its treatment potential

  This study is looking at how a protein called ANGPTL4 affects kidney cancer growth and whether blocking it can help make treatments work better for people with clear cell renal cell carcinoma.

  NIH research University of Florida · Gainesville, United States · NIH-11047156

Related topics

Quick answers

How many Renal Cell Carcinoma clinical trials are recruiting right now?

78, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 29 countries. The most sites are in United States (49 trials), China (12 trials), Italy (9 trials), South Korea (6 trials), United Kingdom (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 19, Phase 1: 12, Phase 1/2: 11, Phase 3: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →